11 results
The primary objective is:* To determine the overall response rate (ORR) of 4 weekly infusions of obinutuzumab monotherapy (Induction I) in patients with rituximab-refractory follicular lymphoma.The secondary objectives are:* To determine the…
This study consists of two research questions: 1. Which treatment (INCS on daily bases versus INCS on demand or versus oral antihistamines on demand) is most effective in reducing nasal symptoms and ocular symptoms in children with mild to moderate…
Objective: Evaluate the safety and effectiveness of two cementless Taperloc versions (Taperloc complete versus Taperloc complete Microplasty)
The primary objective for this study is as follows:* To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used incombination with bendamustine compared with bendamustine alone in patients with indolentNHL refractory to…
The primary objective of the Phase I portion of the study is the following:* To estimate the maximum tolerated dosing schedule for venetoclax given in combination with R-CHOP or G-CHOP to patients with B-cell NHL, either previously untreated or…
The primary objectives of this study are:* To establish the preliminary safety and tolerability profile of RO6958688 in combination with atezolizumab* To determine the maximum-tolerated dose (MTD) in cycle 1 and in later cycles, if achieved, of…
Establish the non-inferiority of the R3 acetabular system with a high survival rate at 10 years fu (at least 90%). Second objective is to establish good clinical results by means of (Harris Hip Score, Hoos, UCLA and radiologic failures (like…
BoneMaster ITo perform a comparative assessment between the clinical, bone remodelling, and radiographic outcomes (as measured with RSA) of the conventional Hydroxyl-Apetite (HA) Taperloc stem compared with Taperloc stem with additional BoneMaster®…
The goal of this clinical investigation is to assess the early migration and bone remodeling of the Symax hip stem and the Trident HA coated or Trident Tritanium acetabulum component with RSA and 18-F PET CT Also the sensitivity of the RSA…
This study will evaluate how safe administering obinutuzumab as a short duration infusion (SDI) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in patients with previously untreated advanced FL is.
Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…